Bristol-Myers Squibb
BMY
Market cap $120B

59.01 USD

-1.27

2.11%

At close Mar 14, 4:00 PM EDT

After hours

59.10

+0.09

0.15%

1 day

-2.11%

5 days

-3.18%

1 month

9.48%

3 months

5.62%

6 months

18.04%

Year to date

3.91%

1 year

12.42%

5 years

15.46%

10 years

-13.26%

About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Employees: 34,100

Healthcare Pharmaceutical Preparations

Funds holding %

of 7,372 funds

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

217% more first-time investments, than exits

New positions opened: 339 | Existing positions closed: 107

50% more funds holding in top 10

Funds holding in top 10: 26 [Q3] → 39 (+13) [Q4]

11% more capital invested

Capital invested by funds: $82B [Q3] → $91.4B (+$9.39B) [Q4]

8% more funds holding

Funds holding: 2,223 [Q3] → 2,408 (+185) [Q4]

0% more call options, than puts

Call options by funds: $1.75B | Put options by funds: $1.75B

0% more repeat investments, than reductions

Existing positions increased: 905 | Existing positions reduced: 901

0.13% more ownership

Funds ownership: 78.25% [Q3] → 78.38% (+0.13%) [Q4]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$55

downside

Avg. target

$63

upside

High target

$70

19%

upside

5 analyst ratings

2 positive

40%

3 neutral

60%

0 negative

Wells Fargo Mohit Bansal 44% 1-year accuracy 12 / 27 met price target	5%upside $62	Equal-Weight Maintained	7 Feb 2025
Cantor Fitzgerald Olivia Brayer 53% 1-year accuracy 10 / 19 met price target	7%downside $55	Neutral Maintained	4 Feb 2025
Citigroup Andrew Baum 67% 1-year accuracy 4 / 6 met price target	10%upside $65	Neutral Maintained	28 Jan 2025
Truist Securities Robyn Karnauskas 24% 1-year accuracy 5 / 21 met price target	10%upside $65	Buy Maintained	8 Jan 2025
Jefferies Akash Tewari 30% 1-year accuracy 3 / 10 met price target	19%upside $70	Buy Upgraded	16 Dec 2024

See Analyst Rankings

Financial journalist opinion

Based on 39 articles about BMY published over the past 30 days

Neutral

Business Wire

2 days ago

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that they own. KSF is seeking to determine whether this consideration and the process that led to.

Neutral

Business Wire

2 days ago

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.

$Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma$